Drug Trial Radar · NCT01616654
Dose Range Study of CD5789 in Acne Vulgaris
Last checked: Nov 19, 2026Latest source record: Sep 20, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
304
Actual
Start
Jun 20, 2012
Primary completion
Jul 24, 2013
Study completion Jun 12, 2014
Sponsor
- Lead sponsor
- Galderma R&DIndustry
- Sponsor type
- Industry
- First posted
- Jun 12, 2012
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 years, up to 35 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To assess the efficacy and safety of different concentrations of CD5789 cream in participants with acne vulgaris for the purpose of dose identification.
Conditions
- Acne Vulgaris
Interventions
CD5789 25 µg/g creamDrug
CD5789 25 µg/g cream applied once daily
CD5789 50 µg/g creamDrug
CD5789 50 µg/g cream applied once daily
CD5789 100 µg/g creamDrug
CD5789 100 µg/g cream applied once daily
Tazarotene 0.1% gelDrug
Tazarotene 0.1% gel applied once daily
Vehicle creamDrug
Vehicle cream applied once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Success Rate 1 (SR1)Time frame: From Baseline at Week 12
- Absolute Change From Baseline in Total Lesion Lesion Counts at Week 12 Using Last Observation Carried Forward (LOCF)Time frame: Baseline, Week 12
- Percentage Change From Baseline in Total Lesion Counts at Week 12 Using Last Observation Carried Forward (LOCF)Time frame: Baseline, Week 12
Locations
24 sites in 1 country. Site status is shown where the registry gives one.
Total Skin and Beauty Dermatology Center, PC
Birmingham, Alabama
Parexel Early Phase
Glendale, California
Odyssey Medispa
Marina del Rey, California
Rady Children's Hospital
San Diego, California
FXM Research Corp Miami
Miami, Florida
FMX Research Miramar
Miramar, Florida
Meda Phase, Inc
Newnan, Georgia
Deaconess Clinic, Inc.
Evansville, Indiana
Dermatology Specialists PC
Louisville, Kentucky
Hamzavi Dermatology
Fort Gratiot, Michigan
Somerset Skin Centre
Troy, Michigan
Skin Specialists, PC
Omaha, Nebraska
Academic Dermatology Associates
Albuquerque, New Mexico
Zoe Drealos, MD
High Point, North Carolina
PMG Research of Wilmington
Wilmington, North Carolina
Central Sooner Research
Norman, Oklahoma
Oregon Dermatology and Research Center
Portland, Oregon
Palmetto Clinical Trial Services, LLC
Greenville, South Carolina
Arlington Center for Dermatology
Arlington, Texas
Suzanne Bruce and Associates P.A. The Center for Skin Research
Houston, Texas
Stephen Miller MD
San Antonio, Texas
Center for Clinical Studies
Webster, Texas
Dermatology Research Center
Salt Lake City, Utah
The Education & Research Foundation, Inc.
Lynchburg, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.